دورية أكاديمية
Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial.
| العنوان: | Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial. |
|---|---|
| المؤلفون: | Kasper S; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. Electronic address: sci-biolpsy@meduniwien.ac.at., Volz HP; Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine Schloss Werneck, Werneck, Germany., Dienel A; Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany., Schläfke S; Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. |
| المصدر: | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2016 Feb; Vol. 26 (2), pp. 331-340. Date of Electronic Publication: 2015 Dec 12. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111390 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7862 (Electronic) Linking ISSN: 0924977X NLM ISO Abbreviation: Eur Neuropsychopharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier, c1990- |
| مواضيع طبية MeSH: | Anti-Anxiety Agents/*therapeutic use , Anxiety/*complications , Anxiety/*drug therapy , Depression/*complications , Depression/*drug therapy , Oils, Volatile/*therapeutic use , Plant Oils/*therapeutic use, Activities of Daily Living ; Adolescent ; Adult ; Aged ; Analysis of Variance ; Double-Blind Method ; Female ; Humans ; Lavandula ; Male ; Middle Aged ; Psychiatric Status Rating Scales ; Quality of Life ; Treatment Outcome ; Young Adult |
| مستخلص: | Mixed anxiety and depressive disorder (MADD; ICD-10 F41.2) is a condition characterized by subsyndromal symptoms of anxiety and depression, neither of which are clearly predominant. Silexan has been demonstrated to be efficacious in subsyndromal and syndromal anxiety disorders and co-morbid depressive symptoms. In this study 318 adult out-patients with MADD according to ICD-10 criteria, a total score ≥18 points on the Hamilton Anxiety Rating Scale (HAMA), and at least moderately severe anxious and depressed mood were randomized and received 1×80mg Silexan or placebo in double-blind fashion for a scheduled period of 70 days. Primary outcome measures were the HAMA and Montgomery Åsberg Depression Rating Scale (MADRS) total score changes between baseline and treatment end. The HAMA total score decreased by 10.8±9.6 points for Silexan and by 8.4±8.9 points for placebo (treatment group difference: p<0.01, one-sided; ANCOVA with factors for treatment and centre and the baseline value as covariate), and total score decreases of 9.2±9.9 and 6.1±7.6 points, respectively, were observed for the MADRS (p<0.001). Compared to placebo, the patients treated with Silexan had a better over-all clinical outcome and showed more pronounced improvements of impaired daily living skills and health related quality of life. Eructation was the only adverse event with a substantially higher incidence under Silexan. The study thus demonstrates that Silexan is efficacious and safe in the treatment of MADD. (Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Anxiety; Clinical trial; Depression; Lavender; Silexan; Treatment efficacy |
| المشرفين على المادة: | 0 (Anti-Anxiety Agents) 0 (Oils, Volatile) 0 (Plant Oils) ZBP1YXW0H8 (lavender oil) |
| تواريخ الأحداث: | Date Created: 20160101 Date Completed: 20161213 Latest Revision: 20211203 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.euroneuro.2015.12.002 |
| PMID: | 26718792 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-7862 |
|---|---|
| DOI: | 10.1016/j.euroneuro.2015.12.002 |